(Q33730978)

Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group (English)

1 reference

stated in

Europe PubMed Central

29 July 2017

1 reference

1 reference

1 reference

1 reference

S Shak

1

1 reference

stated in

Europe PubMed Central

29 July 2017

1 August 1999

1 reference

stated in

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

26

1 reference

stated in

Europe PubMed Central

29 July 2017

71-77

1 reference

stated in

Europe PubMed Central

29 July 2017

4 Suppl 12

1 reference

stated in

Europe PubMed Central

PubMed ID

10482196

retrieved

29 July 2017

Identifiers

PubMed ID

10482196

1 reference

stated in

Europe PubMed Central

PubMed ID

10482196

retrieved

29 July 2017

(Q33730978)

Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)